

Appl. No. : 09/802,397
Filed : March 9, 2001

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method for producing an anti-tumor response in a mammalian subject, said method comprising:

isolating proliferating-dendritic cells from bone marrow, lymph or blood, or, preparing said proliferating-dendritic cells by differentiating *in vitro* proliferating dendritic cell precursors isolated from bone marrow, lymph or blood;

fusing the dendritic cells with tumor cells to form dendritic cell/tumor cell hybrids; and

administering to said subject a plurality of said dendritic cell/tumor cell hybrids, wherein said dendritic cell is not a T-lymphocyte or B-lymphocyte.

2-4. (Cancelled)

5. (Currently amended) The method of Claim 1 wherein the plurality of hybrids is further induced to express ~~the~~-dendritic cell characteristics before using said hybrids for the production of an anti-tumor response.

6. (Cancelled)

7. (Previously presented) The method of Claim 5 wherein said dendritic cell characteristics are chosen from the group consisting of dendritic cell morphology, dendritic cell surface markers or dendritic cell activation markers and immune cell activation properties *in vitro*.

8. (Cancelled)

9. (Previously presented) The method of Claim 5 wherein said induction is performed using GM-CSF.

10. (Cancelled)

11. (Previously presented) The method of Claim 1 wherein the plurality of hybrids is treated to prevent proliferation before using said hybrids for the production of an anti-tumor response.

12. (Cancelled)

13. (Previously presented) The method of Claim 11 wherein said treatment occurs by irradiation.

14. (Cancelled)

Appl. No. : 09/802,397
Filed : March 9, 2001

15. (Previously presented) The method of Claim 1 wherein said plurality of hybrids is administered by injection.

16. (Cancelled)

17. (Previously presented) The method of Claim 15 wherein said injection is carried out parenterally.

18-20. (Cancelled)

21. (Previously presented) The method of Claim 1 wherein said dendritic cell is of myeloid origin.

22. (Cancelled)

23. (Previously presented) The method of Claim 1 wherein said dendritic cell is of lymphoid origin.

24-28. (Cancelled)

29. (Previously presented) The method of Claim 1 wherein the dendritic cell and/or the tumor cell is human in origin.

30-37. (Cancelled)

38. (Currently amended) The method of claim 1, wherein said dendritic cells are prepared by culturing said proliferating dendritic cell precursors in the presence of cytokines so as to induce differentiation.

39-50. (Cancelled)

51. (Previously presented) The method of claim 1, wherein the dendritic cells are isolated from bone marrow, lymph, or blood obtained from the mammalian subject in need of treatment.

52. (Currently amended) The method of claim 1, ~~further comprising selecting the dendritic cell/tumor cell hybrids to obtain a dendritic cell/tumor cell hybridoma, wherein the~~

Appl. No. : **09/802,397**
Filed : **March 9, 2001**

dendritic cell/tumor cell hybridoma is administered to said subject wherein the tumor cells are immortal tumor cells.